Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15873807 | 0.90 | KLKB1 (1.00) | KLKB1KLK1 | |
| SCHEMBL15874007 | 0.89 | KLKB1 (1.00) | KLKB1KLK1 | |
| SCHEMBL15873787 | 0.85 | KLKB1 (1.00) | KLKB1KLK1 | |
| SCHEMBL18544492 | 0.85 | KLKB1 (0.74) | KLKB1KLK1 | |
| SCHEMBL15873968 | 0.85 | KLKB1 (1.00) | KLKB1KLK1 | |
| SCHEMBL15873996 | 0.80 | KLKB1 (1.00) | KLKB1KLK1 | |
| SCHEMBL16486402 | 0.79 | KLKB1 (1.00) | KLKB1KLK1 | |
| SCHEMBL18544493 | 0.79 | KLKB1 (1.00) | KLKB1KLK1 | |
| SCHEMBL28047224 | 0.79 | KLKB1 (0.65) | KLKB1KLK1 | |
| SCHEMBL18544560 | 0.79 | KLKB1 (0.71) | KLKB1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834513-B2 | Benzylamine derivatives | Kalvista Pharmceuticals Limited (GB) | 2017-12-05 | — | — | US | claimed |
| US-20170253561-A1 | Benzylamine Derivatives | KALVISTA PHARMACEUTICALS LTD (GB) | 2017-09-07 | — | — | US | claimed |
| US-9670157-B2 | Benzylamine derivatives | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-06-06 | — | — | US | claimed |
| EP-2943483-B1 | BENZYLAMINE DERIVATIVES | KALVISTA PHARMACEUTICALS LTD (GB) | 2017-03-01 | — | — | EP | claimed |
| US-20160039752-A1 | BENZYLAMINE DERIVATIVES | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-02-11 | — | — | US | claimed |
| EP-2943483-A1 | BENZYLAMINE DERIVATIVES | Kalvista Pharmaceuticals Limited (GB) | 2015-11-18 | — | — | EP | claimed |
| WO-2014108679-A1 | BENZYLAMINE DERIVATIVES | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2014-07-17 | — | — | WO | claimed |
| US-9834513-B2 | Benzylamine derivatives | Kalvista Pharmceuticals Limited (GB) | 2017-12-05 | — | — | US | disclosed |
| US-20170253561-A1 | Benzylamine Derivatives | KALVISTA PHARMACEUTICALS LTD (GB) | 2017-09-07 | — | — | US | disclosed |
| US-9670157-B2 | Benzylamine derivatives | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-06-06 | — | — | US | disclosed |
| EP-2943483-B1 | BENZYLAMINE DERIVATIVES | KALVISTA PHARMACEUTICALS LTD (GB) | 2017-03-01 | — | — | EP | disclosed |
| US-20160039752-A1 | BENZYLAMINE DERIVATIVES | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-02-11 | — | — | US | disclosed |
| EP-2943483-A1 | BENZYLAMINE DERIVATIVES | Kalvista Pharmaceuticals Limited (GB) | 2015-11-18 | — | — | EP | disclosed |
| WO-2014108679-A1 | BENZYLAMINE DERIVATIVES | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2014-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039752-A1 | BENZYLAMINE DERIVATIVES | BDKRB1, BDKRB2, KLKB1 | KLKB1 3/4885KLK1 6/4885 |
| US-20170253561-A1 | Benzylamine Derivatives | BDKRB1, BDKRB2, KLKB1 | KLKB1 3/4885KLK1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.